Between January and February 2024, Delhi deployed handheld digital X-ray devices to conduct targeted tuberculosis (TB) screening in high-risk areas, resulting in the detection of approximately 12,000 TB cases within six weeks (Indian Express, 2024). This initiative was led by the Delhi State TB Cell under the aegis of the National Tuberculosis Elimination Programme (NTEP), a central government scheme implemented by the Ministry of Health and Family Welfare (MoHFW). The rapid identification of TB cases through portable technology marks a significant advance in early diagnosis and aligns with India’s commitment to the End TB Strategy by 2025. The intervention underscores the potential of technology-driven, localized screening to bridge the persistent detection gap in India, which currently notifies only 60% of estimated TB cases annually (NTEP Annual Report 2023).

Legal and Constitutional Framework Governing TB Control in India

Article 21 of the Indian Constitution implicitly guarantees the right to health, forming the basis for state responsibility in TB control. The Epidemic Diseases Act, 1897, provides legal authority for public health emergencies, including communicable disease containment. The NTEP, previously the Revised National Tuberculosis Control Programme (RNTCP), operates under MoHFW guidelines and is the primary institutional mechanism for TB management. Diagnostic regulation is mandated by the Clinical Establishments (Registration and Regulation) Act, 2010, ensuring quality standards for facilities deploying handheld X-rays. The Rights of Persons with Disabilities Act, 2016, specifically Section 32, mandates accessible health services for TB patients with disabilities, integrating equity into TB care.

• Article 21: Right to health and life.
• Epidemic Diseases Act, 1897: Enables containment measures during epidemics.
• NTEP: National TB control and elimination framework.
• Clinical Establishments Act, 2010: Regulates diagnostic service providers.
• Rights of Persons with Disabilities Act, 2016: Ensures accessibility in TB care.

Economic Dimensions of Early TB Detection via Handheld X-rays

India allocates roughly ₹2,000 crore annually to the NTEP as per the Union Budget 2023-24, reflecting sustained fiscal commitment to TB elimination. Early diagnosis through handheld digital X-rays reduces treatment costs by approximately 30%, as it prevents progression to advanced disease stages requiring prolonged and expensive therapy (WHO Global TB Report 2023). Delhi’s recent screening initiative could mitigate indirect economic losses estimated at ₹50,000 crore annually caused by TB-related morbidity and mortality (Stop TB Partnership). The handheld X-ray device market in India is projected to grow at a compound annual growth rate (CAGR) of 8.5% through 2027, driven by increased adoption in public health programs (Market Research Future, 2023).

• Annual NTEP budget: ₹2,000 crore (Union Budget 2023-24).
• Cost reduction: 30% lower treatment expenses with early detection (WHO 2023).
• Economic loss due to TB: ₹50,000 crore annually (Stop TB Partnership).
• Handheld X-ray market CAGR: 8.5% till 2027 (Market Research Future 2023).

Institutional Roles in TB Screening and Control

The NTEP formulates and implements TB control strategies nationwide, with MoHFW providing policy direction and funding. The Indian Council of Medical Research (ICMR) conducts research on TB diagnostics, including efficacy studies on handheld X-rays. The World Health Organization (WHO) offers global guidelines and technical assistance. At the state level, the Delhi State TB Cell operationalizes screening initiatives and monitors outcomes. The Stop TB Partnership advocates for funding and supports programmatic innovations. This multi-institutional ecosystem facilitates the integration of technology into TB detection and treatment pathways.

• NTEP: National implementation and monitoring.
• MoHFW: Policy formulation and resource allocation.
• ICMR: Diagnostic research and validation.
• WHO: Technical guidance and global standards.
• Delhi State TB Cell: Local execution and data collection.
• Stop TB Partnership: Advocacy and funding support.

Data Insights from Delhi’s Handheld X-ray Screening Initiative

Delhi’s TB incidence rate stands at approximately 150 per 100,000 population, slightly below the national average of 193 per 100,000 (NTEP Data 2023). The handheld X-ray screening reduced screening time by 40% compared to conventional methods (ICMR study 2023), enabling rapid case identification. The 12,000 cases detected in six weeks represent a substantial contribution to closing the detection gap. Post-screening, the treatment success rate in Delhi improved from 85% to 90%, indicating better linkage to care and treatment adherence (Delhi State TB Cell Report 2023). However, only about 60% of estimated TB cases are notified nationally, highlighting ongoing challenges in case detection and reporting.

• Delhi TB incidence: 150/100,000 population (NTEP 2023).
• National TB incidence: 193/100,000 population (NTEP 2023).
• Screening time reduction: 40% with handheld X-rays (ICMR 2023).
• Cases detected: 12,000 in 6 weeks (Indian Express 2024).
• Treatment success rate improved from 85% to 90% post-screening (Delhi State TB Cell 2023).
• National notification rate: 60% of estimated cases (NTEP 2023).

Comparative Analysis: India and South Africa’s Mobile TB Screening Models

Critical Gaps in TB Screening and Treatment Continuum

Despite technological progress, integration of TB screening with primary healthcare remains insufficient. Many programs, including Delhi’s, lack comprehensive follow-up mechanisms post-diagnosis, leading to loss to follow-up and under-treatment. This gap undermines the potential gains from early detection. Furthermore, the absence of systematic screening integration with other communicable and non-communicable disease programs limits holistic patient management. Addressing these gaps is essential to sustain improvements in TB control and meet national elimination targets.

• Inadequate integration with primary healthcare services.
• Insufficient post-diagnosis follow-up and treatment adherence tracking.
• Limited linkage with other disease control programs.
• Potential for increased loss to follow-up and under-treatment.

Significance and Way Forward

Delhi’s handheld X-ray screening initiative demonstrates the scalability and efficacy of technology-enabled TB detection in high-burden urban settings. Expanding such interventions nationally can accelerate case detection and reduce transmission. Policy focus should include strengthening follow-up systems, integrating TB screening with primary healthcare, and ensuring regulatory compliance under the Clinical Establishments Act. Budgetary allocations must sustain investments in portable diagnostic technologies and capacity building. Collaboration between NTEP, ICMR, state TB cells, and global partners like WHO and Stop TB Partnership is critical to optimize outcomes and achieve India’s End TB targets by 2025.

• Scale up handheld X-ray screening in other high-risk regions.
• Integrate TB screening with primary healthcare and other disease programs.
• Enhance follow-up and treatment adherence mechanisms.
• Ensure regulatory oversight of diagnostic services.
• Increase budgetary support for technology and human resources.

Jharkhand & JPSC Relevance

• JPSC Paper: Paper 2 – Health and Social Welfare, Disease Control Programmes
• Jharkhand Angle: Jharkhand faces a high TB burden with rural and tribal populations; handheld X-ray screening can improve early detection in remote areas.
• Mains Pointer: Emphasize the role of portable diagnostics in overcoming geographical barriers and the need for state-level capacity building aligned with NTEP.